The Delhi High Court said Tuesday that no coercive steps be taken against drug companies for FDCs already in market, subject to stopping of their manufacturing.
Justice Vibhu Bakhru granted the relief to some drug manufacturers after they approached the high court.
It had said earlier that no coercive steps be taken against Indian pharma major Wockhardt for sale of stock, already in the market, of its anti-inflammatory medicine which has been banned, subject to the company stopping further production of the drug.
The court, in an interim order, had said the medicine, one of 328 fixed dose combination (FDC) drugs banned by the Centre a week ago, has been in the market for past 11 years and its stocks would already be in the distribution network.
The ministry by its September 7 notification had banned the manufacture, sale and distribution of 328 FDC drugs. FDCs are two or more drugs combined in a fixed ratio into a single dosage form.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
